Active	Status	Sponsor type	Region	Phase	Filter
2 Active 10 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lai, Xun
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma	Active, not recruiting	3	85	RoW	Pomalidomide, Dexamethasone	Qilu Pharmaceutical Co., Ltd.	Multiple Myeloma, Recurrent or Refractory	06/22	12/23
NCT06082102: Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma	Recruiting	3	324	RoW	Orelabrutinib, Lenalidomide, Rituximab, Orelabrutinib Placebo	Beijing InnoCare Pharma Tech Co., Ltd.	Relapsed/Refractory Marginal Zone Lymphoma	08/27	02/30